Name
Cyprotex, an Evotec Company
What We Do
Founded in 1999, Cyprotex has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec in 2016. The Evotec Group offers expert support from early discovery through to clinical development.
Website
Product or Service Categories (15)
Cardiology/Cardiotoxicology, Genotoxicity, Immunology, Mechanistic Toxicology, Neurobiology/Neurotoxicology, Regulatory Toxicology, Toxicogenomics, ADME (Absorption/Distribution/Metabolism/Excretion), CRO—Contract Research Organization, In Vitro, Bioanalytical Services, Consulting/Professional Services, High Throughput Test Systems, Microarrays, Safety/Risk Assessment